2019
DOI: 10.1093/ofid/ofz360.1962
|View full text |Cite
|
Sign up to set email alerts
|

2284. Treatment and Clinical Outcomes Among Infected Patients with Colistin-resistant Klebsiella pneumoniae Bacteremia.

Abstract: BackgroundIn recent years, the emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) and colistin-resistant Klebsiella pneumoniae (CoRKP) is one of the leading causes of nosocomial infection worldwide. It has become a public health concern and high mortality, which the few treatment options are available. Salvage treatment caused by CoRKP is still unknown. Here, we explored the 14-day and in hospital mortality to understand the threat to clinical and public health. In addition, we determined the treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 0 publications
0
5
1
Order By: Relevance
“…Therefore, when ceftazidime–avibactam cannot be used, old antibiotics remain the treatment option for carbapenem-resistant Enterobacterales . Fosfomycin is one of the antibiotics in combination regimens [ 26 35 ]. IV fosfomycin has been fairly used for treating infections with P. aeruginosa.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, when ceftazidime–avibactam cannot be used, old antibiotics remain the treatment option for carbapenem-resistant Enterobacterales . Fosfomycin is one of the antibiotics in combination regimens [ 26 35 ]. IV fosfomycin has been fairly used for treating infections with P. aeruginosa.…”
Section: Discussionmentioning
confidence: 99%
“…It is important to note CRE treatment requires the use of antimicrobial combinations to improve clinical outcomes and prevention of fosfomycin resistance [ 5 16 40 ]. The beneficial synergism of fosfomycin dosed in combination with powerful antimicrobials, such as colistin or tigecycline, might be necessary to attain higher PTA targets and to reduce fosfomycin MIC's against CRE isolates [ 7 8 ]. Therefore, in an immunocompromised host or difficult-to-treat infection, it is likely fosfomycin should be combined with other antibiotics, and 100% T>MIC should be targeted.…”
Section: Discussionmentioning
confidence: 99%
“…These pathogens are known to develop antibiotic resistance through loss of porin or by carbapenemase production. Furthermore, infections caused by CRE organisms remain an important public health concern in many countries throughout the world, including Thailand [7]. For these reasons, proper selection of effective antimicrobial 523 https://icjournal.org https://doi.org/10.3947/ic.2020.52.4.516 agents and the use of optimal dosing regimens is essential to reducing morbidity and mortality in patients infected with CRE bacteria [23].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations